Table 5 The clinical data analysis of COVID-19 confirmed patients
From: Rapid identification of COVID-19 severity in CT scans through classification of deep features
Characteristics | Total cases (N = 202) | Non-severely ill (N = 161) | Severely ill (N = 41) | P |
|---|---|---|---|---|
Clinical data | ||||
Gender (male) | 110 (54.5%) | 82 (50.9%) | 28 (68.3%) | 0.01 |
Age (mean ± S.D., year) | 46.4 ± 15.554 | 43.7 ± 14.600 | 57.0 ± 14.782 | < 0.001 |
Coexisting Illness | 53 (26.2%) | 30 (18.6%) | 23 (56.1%) | < 0.001 |
Symptoms | ||||
Fever | 157 (77.7%) | 118 (73.3%) | 39 (95.1%) | 0.523 |
Cough | 109 (54.0%) | 82 (50.9%) | 27 (65.9%) | 0.087 |
Sputum production | 48 (23.8%) | 38 (23.6%) | 10 (24.4%) | 0.916 |
Sore throat | 17 (8.4%) | 15 (9.3%) | 2 (4.9%) | 0.361 |
Nausea/headache | 11 (5.4%) | 9 (5.6%) | 2 (4.9%) | 0.858 |
Myalgia or arthralgia | 15 (7.4%) | 12 (7.5%) | 3 (7.3%) | 0.976 |
Shortness of breath | 16 (7.9%) | 11 (6.8%) | 5 (12.2%) | 0.256 |
Others | 8 (4.0%) | 8 (5.0%) | 0 (0%) | 0.145 |
Laboratory findings | ||||
Increase of CRP | 129 (63.9%) | 92 (57.1%) | 37 (90.2%) | < 0.001 |
WBCs abnormalitya | 73 (36.1%) | 50 (31.1%) | 23 (56.1%) | 0.011 |
Lymphocytes abnormalitya | 109 (54.0%) | 76 (47.2%) | 33 (80.5%) | < 0.001 |
Fever | ||||
High fever | 12 (5.9%) | 2 (1.2%) | 10 (24.4%) | < 0.001 |
Low fever | 145 (71.8%) | 116 (72.0%) | 29 (70.7%) | 0.867 |
Travel or contact history | 92 (45.5) | 79 (49.1%) | 13 (31.7%) | 0.046 |